TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34727741

Group type: EXPERIMENTAL
Intervention: Bridging therapy
Number of subjects: 1872

Group type: COMPARATOR
Intervention: Mechanical thrombectomy (MT) alone
Number of subjects: 1872

Group type: COMPARATOR
Intervention: Intravenous thrombolysis alone
Number of subjects: 1872
Study: 34727875

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (Abraxane, 125 mg/m2, D1, D8, D15 every 28 days)
Number of subjects: 80
Study: 34727956

Group type: EXPERIMENTAL
Intervention: MedReviewRx software used for medication reviews
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (before intervention)
Number of subjects: 1000
Study: 34727972

Group type: EXPERIMENTAL
Intervention: Home-based salivary sampling protocol
Number of subjects: 19
Study: 34727975

Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Number of subjects: 94

Group type: COMPARATOR
Intervention: Low fat diet
Number of subjects: 94
Study: 34728052

Group type: EXPERIMENTAL
Intervention: Mandibular advancement device therapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 63
Study: 34728392

Group type: EXPERIMENTAL
Intervention: Blood gas analysis (bicarbonate, partial pressure of oxygen, and partial pressure of carbon dioxide)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Blood gas analysis
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Vascular collateralization assessment
Number of subjects: 62
Study: 34728440

Group type: EXPERIMENTAL
Intervention: Message-based care only for 6 weeks
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Videoconference-psychotherapy only for 6 weeks
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Monthly videoconference-psychotherapy
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Weekly videoconference-psychotherapy plus message-based care
Number of subjects: 1000
Study: 34728446

Group type: EXPERIMENTAL
Intervention: MyPal digital health platform (n=150)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard care (n=150)
Number of subjects: 300
Study: 34728455

Group type: EXPERIMENTAL
Intervention: Deep learning techniques including convolutional neural network, recurrent neural network, and Transformer applied to primary care data for predicting new-onset AF.
Number of subjects: 0
Study: 34728530

Group type: EXPERIMENTAL
Intervention: Confirmed Diabetic Peripheral Neuropathy (DPN) in men at EDIC year 13/14
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Abnormal Michigan Neuropathy Screening Instrument (MNSI) examination or questionnaire scores in men
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Women with FSD and LUTS/UI
Number of subjects: 1006
Study: 34728783

Group type: EXPERIMENTAL
Intervention: Athletes with SCI
Number of subjects: 145

Group type: COMPARATOR
Intervention: Able-bodied controls
Number of subjects: 145

Group type: COMPARATOR
Intervention: Non-athletes with SCI
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Athletes with SCI and able-bodied controls
Number of subjects: 145
Study: 34729148

Group type: EXPERIMENTAL
Intervention: Optimal Medical Therapy (OMT)
Number of subjects: 765

Group type: COMPARATOR
Intervention: Non-Optimal Medical Therapy (non-OMT)
Number of subjects: 765
Study: 34729526

Group type: EXPERIMENTAL
Intervention: ATTRwt amyloidosis diagnoses in the United States
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: ATTRwt amyloidosis diagnoses by tissue biopsy
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: ATTRwt amyloidosis diagnoses by bone scintigraphy
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: ATTRv amyloidosis with cardiac mutation diagnoses
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: Proportion of patients with ATTRwt amyloidosis diagnosed with NYHA functional class III/IV heart failure
Number of subjects: 1069
Study: 34729628

Group type: EXPERIMENTAL
Intervention: knottin PET/CT
Number of subjects: 15
Study: 34729682

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (0.6 mg)
Number of subjects: 0
Study: 34729767

Group type: EXPERIMENTAL
Intervention: Hyperfibrinolysis defined as enzymatic fibrinolysis index (ROTEM EXTEM ML minus ROTEM APTEM ML) above 15%
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Enzymatic fibrinolysis index > 15%
Number of subjects: 390
Study: 34730004

Group type: EXPERIMENTAL
Intervention: Newly diagnosed infections during hospitalization
Number of subjects: 2399

Group type: COMPARATOR
Intervention: No newly diagnosed infections during hospitalization
Number of subjects: 2399
Study: 34730535

Group type: EXPERIMENTAL
Intervention: Smartphone-enhanced behavioral activation treatment (Life Enhancement Treatment for Substance Use)
Number of subjects: 56
Study: 34730541

Group type: EXPERIMENTAL
Intervention: Online therapy
Number of subjects: 6023

Group type: COMPARATOR
Intervention: Face-to-Face therapy (F2F)
Number of subjects: 6023

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 6023
Study: 34731011

Group type: EXPERIMENTAL
Intervention: OSATURBS Assessment Tool
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 34731867

Group type: EXPERIMENTAL
Intervention: MIMS procedure (ab interno, stent-less, subconjunctival filtration)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: MIMS procedure (with iris clogging complication)
Number of subjects: 31
Study: 34731884

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant (auto-SCT) for ELN2017-FR patients
Number of subjects: 500

Group type: COMPARATOR
Intervention: Allogeneic stem cell transplant (allo-SCT) for ELN2017-FR patients
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant (auto-SCT) for ELN2017-IR patients
Number of subjects: 500

Group type: COMPARATOR
Intervention: Allogeneic stem cell transplant (allo-SCT) for ELN2017-IR patients
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: ELN2017-FR group
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: ELN2017-IR group
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: ELN2017-not classifiable group
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: ELN2017-AR group
Number of subjects: 500
Study: 34732137

Group type: EXPERIMENTAL
Intervention: Hypotaurine supplementation (H+)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (H-)
Number of subjects: 33
Study: 34732178

Group type: EXPERIMENTAL
Intervention: TEACHH intervention
Number of subjects: 78
Study: 34732233

Group type: EXPERIMENTAL
Intervention: Group SS - ONS in addition to normal diet up to 14 days preoperatively and postoperatively up to discharge
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Group SS-E - ONS in addition to normal diet up to 14 days preoperatively, postoperatively up to discharge and for an extended 90 days after discharge
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Group DS - ONS in addition to normal diet postoperatively up to discharge
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Group SS, Group SS-E, Group DS - ONS
Number of subjects: 3
Study: 34732246

Group type: EXPERIMENTAL
Intervention: FABIANA-checklist (25-item version)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: FABIANA-checklist
Number of subjects: 75
Study: 34732425

Group type: EXPERIMENTAL
Intervention: Non-smokers
Number of subjects: 2439

Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 2439
Study: 34732475

Group type: EXPERIMENTAL
Intervention: Access to grocery store
Number of subjects: 9218

Group type: EXPERIMENTAL
Intervention: Access to public transport stop
Number of subjects: 9218

Group type: EXPERIMENTAL
Intervention: Access to children's playground
Number of subjects: 9218

Group type: EXPERIMENTAL
Intervention: Access to metropolitan parks
Number of subjects: 9218

Group type: EXPERIMENTAL
Intervention: Proximity to sport facilities or children's playground areas
Number of subjects: 9218

Group type: EXPERIMENTAL
Intervention: Perception of adequate design for walking or cycling
Number of subjects: 9218

Group type: EXPERIMENTAL
Intervention: Perception of living in a safe neighbourhood
Number of subjects: 9218
Study: 34732478

Group type: EXPERIMENTAL
Intervention: Nudge alert addressing patient harm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nudge alert addressing increased out-of-pocket costs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nudge alert addressing psychological harm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nudge alerts (all types)
Number of subjects: 0
Study: 34732483

Group type: EXPERIMENTAL
Intervention: Workplace exercise intervention (2 hours of exercise per week for 12 weeks)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Delayed intervention group (2 hours of exercise per week for 4 weeks after the initial intervention)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Workplace exercise intervention
Number of subjects: 150
Study: 34732486

Group type: EXPERIMENTAL
Intervention: Robotic-assisted partial nephrectomy (RAPN)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Open partial nephrectomy (OPN)
Number of subjects: 50
Study: 34732500

Group type: EXPERIMENTAL
Intervention: Lengthened dosing interval (from 8 to 12 weeks for infliximab users and from 2 to 3 weeks for adalimumab users)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Standard dosing
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Lengthened dosing interval
Number of subjects: 148
Study: 34732666

Group type: EXPERIMENTAL
Intervention: Subluxation supracapsular phacoemulsification
Number of subjects: 292

Group type: COMPARATOR
Intervention: Divide-and-conquer phacoemulsification
Number of subjects: 292
Study: 34732682

Group type: EXPERIMENTAL
Intervention: Atazanavir 300 mg and Cobicistat 150 mg orally once daily during the second trimester
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Atazanavir 300 mg and Cobicistat 150 mg orally once daily during the third trimester
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Atazanavir 300 mg and Cobicistat 150 mg orally once daily postpartum
Number of subjects: 11
Study: 34733163

Group type: EXPERIMENTAL
Intervention: BuqiTongluo Granule
Number of subjects: 0
Study: 34733947

Group type: EXPERIMENTAL
Intervention: CTCA prior to angiography
Number of subjects: 688

Group type: COMPARATOR
Intervention: ICA alone
Number of subjects: 688
Study: 34734199

Group type: EXPERIMENTAL
Intervention: 12-session group-based parenting programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment-as-usual services
Number of subjects: 0
Study: 34734223

Group type: COMPARATOR
Intervention: Light drinkers (>2 to 10 g/d)
Number of subjects: 4365

Group type: COMPARATOR
Intervention: Moderate drinkers (>10 to 30 g/d)
Number of subjects: 4365

Group type: COMPARATOR
Intervention: Heavy drinkers (>30 g/d)
Number of subjects: 4365

Group type: EXPERIMENTAL
Intervention: Nondrinkers (0 g/d) and very light drinkers (>0 to 2 g/d)
Number of subjects: 4365
Study: 34734507

Group type: EXPERIMENTAL
Intervention: Drug-induced IL-22 releasing cells
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Drug-induced IFN-γ releasing cells
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Drug-induced GrB releasing cells
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combined IFN-γ/IL-22/GrB ELISpot
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Alpha-galactosylceramide supplementation
Number of subjects: 27
Study: 34734825

Group type: EXPERIMENTAL
Intervention: Klondike Solitaire (played by participants living with MCI)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Klondike Solitaire (played by healthy participants)
Number of subjects: 46
Study: 34734828

Group type: EXPERIMENTAL
Intervention: P3 app (Prepared, Protected, emPowered)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: P3 app adaptations
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Focus group discussions (FGDs)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Adaptation process
Number of subjects: 23
Study: 34734835

Group type: EXPERIMENTAL
Intervention: 12 sessions of twice weekly EMDR plus treatment as usual
Number of subjects: 80

Group type: COMPARATOR
Intervention: Treatment as usual alone
Number of subjects: 80
Study: 34734839

Group type: EXPERIMENTAL
Intervention: Door-to-door screening and awareness generation activities in 8-12 villages surrounding the VCs.
Number of subjects: 2

Group type: COMPARATOR
Intervention: Existing practices of awareness generation through community activities and health talks.
Number of subjects: 2
Study: 34735517

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 144
Study: 34735695

Group type: EXPERIMENTAL
Intervention: Electronic psycho-oncological adaptive screening (EPAS)
Number of subjects: 660
Study: 34735860

Group type: EXPERIMENTAL
Intervention: Acalabrutinib 200 mg twice daily as monotherapy
Number of subjects: 25
Study: 34736130

Group type: EXPERIMENTAL
Intervention: Extended-release buprenorphine injections (BUP-XR), administered monthly after a minimum of 7 days on 8-32 mg of sublingual buprenorphine (±naloxone)
Number of subjects: 100
Study: 34736158

Group type: EXPERIMENTAL
Intervention: RBANS (Repeatable Battery for Assessment of Neuropsychological Status)
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: PSP cognitive composite score
Number of subjects: 486
Study: 34736497

Group type: EXPERIMENTAL
Intervention: Scalp nerve blocks with 0.5% bupivacaine plus dexamethasone (exact dosage not specified)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Scalp nerve blocks with 0.5% bupivacaine plus normal saline with epinephrine at 1:200,000
Number of subjects: 156
Study: 34736503

Group type: EXPERIMENTAL
Intervention: Insertion of ventilation tubes
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: History of adenoidectomy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Use of hearing aids
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Hearing loss in at least one ear
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Hearing loss in youngest age group (16-44 years)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Abnormal tympanometry (Type B or C)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Conductive hearing loss or combination of conductive and sensorineural hearing loss
Number of subjects: 45
Study: 34736538

Group type: EXPERIMENTAL
Intervention: Idiographic network analysis for personalized treatment targets
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Selection methods for treatment targets
Number of subjects: 34
Study: 34736561

Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve replacement (TMVR)
Number of subjects: 100
Study: 34736741

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34736789

Group type: EXPERIMENTAL
Intervention: Preoperative soluble urokinase plasminogen activator receptor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative soluble urokinase plasminogen activator receptor between 5.5 and 10 ng/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative soluble urokinase plasminogen activator receptor >10 ng/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic analysis of soluble urokinase plasminogen activator receptor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic analysis combining age, sex, C-reactive protein levels, and American Society of Anesthesiologists score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adding soluble urokinase plasminogen activator receptor to the model
Number of subjects: 0
Study: 34736820

Group type: EXPERIMENTAL
Intervention: COPE for Asthma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mindstrong to Combat Bullying
Number of subjects: 0
Study: 34737035

Group type: EXPERIMENTAL
Intervention: Persistently low hsCRP (hsCRP ≤ 2 mg/L)
Number of subjects: 1018

Group type: EXPERIMENTAL
Intervention: Falling hsCRP (first high then low)
Number of subjects: 1018

Group type: EXPERIMENTAL
Intervention: Rising hsCRP (first low then high)
Number of subjects: 1018

Group type: EXPERIMENTAL
Intervention: Persistently high hsCRP (hsCRP > 2 mg/L)
Number of subjects: 1018
Study: 34737791

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AFib)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sinus rhythm (SR)
Number of subjects: 0
Study: 34738049

Group type: EXPERIMENTAL
Intervention: Three-cluster model
Number of subjects: 235
Study: 34738090

Group type: EXPERIMENTAL
Intervention: Paclitaxel, Ifosfamide, and Cisplatin (TIP)
Number of subjects: 19
Study: 34738141

Group type: EXPERIMENTAL
Intervention: Bevacizumab-800CW (10 mg intravenously administered 3 days prior to surgery)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Fluorescence grid analysis
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: VEGF-A as a target
Number of subjects: 5
Study: 34738340

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (n = 68)
Number of subjects: 239

Group type: COMPARATOR
Intervention: No sacubitril/valsartan (n = 164)
Number of subjects: 239
Study: 34738853

Group type: EXPERIMENTAL
Intervention: Galectin-3 measurement
Number of subjects: 0
Study: 34739006

Group type: EXPERIMENTAL
Intervention: Perturbation training using mechatronic shoes
Number of subjects: 35
Study: 34739085

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34739137

Group type: EXPERIMENTAL
Intervention: Surgery in children with SARS-CoV-2 infection
Number of subjects: 0
Study: 34739191

Group type: EXPERIMENTAL
Intervention: Intervention using pharmacy refill data to monitor nonadherence and prompt discussions during clinic encounters.
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Provider surveys measuring feasibility, acceptability, and appropriateness of the intervention.
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Patient surveys measuring reactions to the intervention visit.
Number of subjects: 130
Study: 34739334

Group type: EXPERIMENTAL
Intervention: Participatory prototyping of tailored U=U messaging developed in workshops
Number of subjects: 39
Study: 34739527

Group type: EXPERIMENTAL
Intervention: 1.5 g Vitamin C 4 times a day during 4 days, started within 6 hours after admission
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 300
Study: 34739582

Group type: EXPERIMENTAL
Intervention: Lurbinectedin 3.2 mg/m
Number of subjects: 0
Study: 34739844

Group type: EXPERIMENTAL
Intervention: Ibrutinib plus R-CHOP chemotherapy
Number of subjects: 2

Group type: COMPARATOR
Intervention: R-CHOP chemotherapy alone
Number of subjects: 2
Study: 34740349

Group type: EXPERIMENTAL
Intervention: Family caregivers of critically ill adults with delirium
Number of subjects: 147
Study: 34740593

Group type: EXPERIMENTAL
Intervention: Any respiratory symptom
Number of subjects: 4621

Group type: EXPERIMENTAL
Intervention: Cough or phlegm
Number of subjects: 4621

Group type: EXPERIMENTAL
Intervention: Wheeze
Number of subjects: 4621

Group type: EXPERIMENTAL
Intervention: Shortness of breath
Number of subjects: 4621

Group type: EXPERIMENTAL
Intervention: Chest illnesses
Number of subjects: 4621

Group type: COMPARATOR
Intervention: Zero vs three to four respiratory symptoms
Number of subjects: 4621
Study: 34740742

Group type: EXPERIMENTAL
Intervention: Empagliflozin (25 mg/day)
Number of subjects: 362
Study: 34740768

Group type: EXPERIMENTAL
Intervention: Salvage low-dose-rate (LDR) prostate brachytherapy (BT)
Number of subjects: 92
Study: 34740876

Group type: EXPERIMENTAL
Intervention: EarlySense under-mattress device
Number of subjects: 76

Group type: COMPARATOR
Intervention: Masimo Rad-97 pulse CO-oximeter with capnography reference device
Number of subjects: 76
Study: 34740929

Group type: EXPERIMENTAL
Intervention: Urban setting
Number of subjects: 200

Group type: COMPARATOR
Intervention: Rural setting
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Annual eye examinations and questionnaires
Number of subjects: 200
Study: 34740986

Group type: EXPERIMENTAL
Intervention: Coiling
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Balloon-assisted coiling (BAC)
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Ruptured aneurysms
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Aneurysm size ≥10 mm
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Wide neck aneurysms
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: MCA location
Number of subjects: 908
Study: 34741021

Group type: EXPERIMENTAL
Intervention: trastuzumab emtansine (T-DM1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: trastuzumab emtansine/pertuzumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: trastuzumab/paclitaxel
Number of subjects: 0
Study: 34741102

Group type: EXPERIMENTAL
Intervention: Enteral sildenafil (cohort 1)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: IV sildenafil 0.25 mg/kg (cohort 2)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: IV sildenafil 0.125 mg/kg (cohort 2)
Number of subjects: 32
Study: 34741172

Group type: EXPERIMENTAL
Intervention: CAPA-AREG (medium with amphiregulin 100 ng/ml)
Number of subjects: 30

Group type: COMPARATOR
Intervention: CAPA-Control (medium without amphiregulin)
Number of subjects: 30
Study: 34741189

Group type: EXPERIMENTAL
Intervention: Treatment limitations
Number of subjects: 0
Study: 34741240

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 264

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 264
Study: 34741321

Group type: EXPERIMENTAL
Intervention: Transcortical miniscrew placed over the buccal plate of the extraction socket
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control side (untreated extraction socket)
Number of subjects: 6
Study: 34741536

Group type: EXPERIMENTAL
Intervention: Exercise-based cardiac rehabilitation (CR)
Number of subjects: 23430
Study: 34741779

Group type: EXPERIMENTAL
Intervention: Psycho-education intervention for parents, consisting of two workshops of 2 hours each.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Waitlist control group (no intervention).
Number of subjects: 70
Study: 34741794

Group type: EXPERIMENTAL
Intervention: Arcing stroke pattern
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Semicircular (SC) stroke pattern
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Single-loop (SL) stroke pattern
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Double-loop (DL) stroke pattern
Number of subjects: 40
Study: 34741822

Group type: EXPERIMENTAL
Intervention: COVID-19 sequelae
Number of subjects: 2634

Group type: EXPERIMENTAL
Intervention: Permanent treatment discontinuation
Number of subjects: 2634

Group type: EXPERIMENTAL
Intervention: Dose or regimen adjustment
Number of subjects: 2634